TMCnet News

Trevena CEO to Present at the 9th Annual JMP Securities Healthcare Conference
[June 18, 2014]

Trevena CEO to Present at the 9th Annual JMP Securities Healthcare Conference


KING OF PRUSSIA, Pa. --(Business Wire)--

Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its president and chief executive officer, will present at the 9th Annual JMP Securities (News - Alert) Healthcare Conference on Wednesday, June 25, 2014 at 11:00 a.m. EDT at The Westin Grand Central in New York City.

To access a live audio webcast of the presentation, please visit the "Investors" section at www.trevenainc.com. The webcast will be archived for 30 days.



About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic - TRV027 to treat acute heart failure, TRV130 to treat moderate-to-severe acute pain intravenously, and TRV734 to treat moderate-to-severe acute and chronic pain orally. Trevena also is advancing additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.



[ Back To TMCnet.com's Homepage ]